Protalix BioTherapeutics (PLX) -18.4% premarket as it says the FDA extends the goal date for...

|About: Protalix BioTherapeutics, Inc (PLX)|By:, SA News Editor

Protalix BioTherapeutics (PLX) -18.4% premarket as it says the FDA extends the goal date for approving its new drug application for taliglucerase alfa, a treatment for Gaucher disease, to May 1 from Feb. 1. Protalix says no additional data was requested by the FDA, nor was the company notified of any specific deficiency in the application.